Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Outer membrane protein PorA (P1.4) is a major surface-exposed protein of Neisseria meningitidis, the bacterium responsible for invasive meningococcal disease, including meningitis and sepsis [1, 6]. It functions as a cation-selective porin, forming trimeric channels in the outer membrane that facilitate the transport of small molecules and nutrients [6]. The P1.4 designation refers to a specific serosubtype defined by the sequence of its variable regions (VR1 and VR2), which are the primary targets for host immune responses [8]. Due to its high immunogenicity, PorA P1.4 is a critical component of several meningococcal B vaccines, such as Bexsero and MeNZB, where it is typically presented within outer membrane vesicles (OMVs) [2, 4]. These vaccines work by inducing bactericidal antibodies that trigger complement-mediated killing of the bacteria [4, 7]. However, the effectiveness of PorA-targeted therapies is challenged by the protein's high degree of antigenic variation and phase variation, which allow the bacteria to escape immune detection [1, 8]. Consequently, PorA-based protection is often strain-specific, necessitating the inclusion of multiple antigens in modern vaccine formulations [4, 13].
Induction of host bactericidal antibodies that recognize the PorA protein on the bacterial surface, triggering the classical complement pathway and resulting in complement-mediated lysis and opsonophagocytosis of Neisseria meningitidis [4, 7].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class 1 outer membrane protein PorA (P1.4) (PorA P1.4).